Figure 2

Panel A. Changes in lymphocyte subsets associated with chemotherapy and GM-CSF administration. Individual lymphocyte subsets were evaluated by flow cytometry before and after the administration of chemotherapy and GM-CSF. The subsets that were evaluated include: CD4+, CD8 +, CD4+CD25 high (Treg), CD56+ CD3+ (NK-T) populations. Values depicted represent average percentages of nucleated cells in whole blood samples (n = 23) with error bars depicting standard error values. Significant differences were evaluated with a Wilcoxon matched pairs test. The decrease in CD4 and CD8 T lymphocyte subsets was statistically significant at p = 0.0064 and p = 0.0012 respectively. The decrease in the Treg population was also significant at p = 0. 0042 while the decrease in NK-T cells approached statistical significance p = 0.0997. Panel B. Percent change in lymphocyte subsets across multiple cycles of chemotherapy & GM-CSF. In the first and subsequent cycles of Chemotherapy & GM-CSF the percent change in lymphocyte subsets that include: CD4+, CD8 +, CD4+CD25 high (Treg), CD56+ CD3+ (NK-T) populations, were determined. Percent change was calculated in the standard fashion [(pre- treatment value - post-treatment value)/pre-treatment value] × 100. None of the differences in lymphocyte subset changes between the first and subsequent cycles reached statistical significance by two-tailed unpaired t-test with Welch's correction. Panel C. Changes in monocytes and myeloid DCs associated with chemotherapy and GM-CSF administration. Individual cell populations were evaluated by flow cytometry before and after the administration of chemotherapy and GM-CSF. Monocyte populations were identified as being CD14+. Myeloid dendritic cells (DCs) were identified using a lineage cocktail (CD3, CD20, CD14, CD56) negative cells that had MHC II high expression. Values depicted represent average percentages of nucleated cells in whole blood samples (n = 23) with error bars depicting standard error values. Differences were evaluated with a Wilcoxon matched pairs test. Differences in monocytes and DCs were statistically significant p = 0.0214 and p = 0.0198 respectively. Panel D. Percent change in monocytes and dendritic cells across multiple cycles of chemotherapy and GM-CSF. In the first and subsequent cycles of Chemotherapy & GM-CSF the percent change in monocytes (CD14+ cells) and dendritic cells (DCs) [lineage cocktail (CD3, CD20, CD14, CD56) negative, MHC II high expression] were determined. Percent change was calculated in the standard fashion [(pre-treatment value - post-treatment value)/pre-treatment value] × 100. None of the differences in lymphocyte subset changes between the first and subsequent cycles reached statistical significance by two-tailed unpaired t-test with Welch's correction.